France Archives

News and Trends 14 Sep 2015

High-Throughput screening of drug candidates made easier by FRETinFLOW

A multidisciplinary team from France has come up with a robust approach to detect molecular interactions in a reliable way using flow cytometry. This technology could lead to the discovery of new drugs via High-Throughput screening. Flow cytometry is a laser-based, biophysical technology employed by scientists all over the world to count and sort cells. It does this by […]

September 14, 2015 - 4 minutesmins - By Joachim Eeckhout

News and Trends 11 Sep 2015

Biom’Up funding goes up Up UP! Surgery tech gets new pot of €31.3M VC

Biom’Up is a Lyon (Fr) Med-tech company which produces biopolymer devices to improve surgery. Launch of their new product Hemoblast has triggered a series C investment round from a large syndicate of European venture capitals. Biom’Up was founded in 2005, experiencing exponential growth since with their biopolymer tech development which achieved a €3M turnover in […]

September 11, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 11 Sep 2015

Biofuels from tobacco: US Tyton and French Deinove partner up

The French green Biotech Deinove continues to strengthen its position in the New World after sealing a new agreement with an American company. Deinove and Tyton BioEnergy systems will bring new solutions to the green chemicals market sector. Deinove’s technology platform produces biofuels and bio-based chemicals by using Deinococcus bacteria as host strains. The bioprocess […]

September 11, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 10 Sep 2015

Roche adds AveXis to its SMA portfolio – determined to dominate market

Swiss Roche is looking to dominate market in Spinal Muscular Atrophy (SMA) research, now also investing in AveXis as part of €58M series D investment in their SMA one-time treatment pipeline. Other veteran VC parties include Deerfield Management and Venrock, with new investors also looking to claim a stake in AveXis SMA candidate treatment. SMA […]

September 10, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 10 Sep 2015

Genkyotex’ NOX inhibitor candidate Fails to follow through on Phase II

The French biotech Genkyotex has announced Phase II results for GKT137831 in diabetic kidney disease. The NOX1-4 inhibitor failed to reduce albuminuria. Genkyotex focuses on developing inhibitors of nicotinamide adenine dinucleotide phosphate-oxidase (NADPH) enzymes which are expressed by the NOX-gene family (NOX 1-5). NOX enzymes generate reactive oxidative species (ROS) which if overproduced, can cause […]

September 10, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 9 Sep 2015

Encouraging results from Tedopi Phase II trials in patients with brain metastases

French Immuno-oncology Biotech OSE Pharma has announced its phase II results for Tedopi trials showing outcome for patients with brain metastases. Announced at the World Conference on Lung Cancer in Denver (US), OSE Pharma revealed how Tedopi had shown interesting results in patients diagnosed with brain metastases from advanced non-small cell lung cancer. Advanced non-small […]

September 9, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 7 Sep 2015

A Slice of Europe: MD Anderson looks to invest in EU Immuno-Oncology

MD Anderson is expanding its Immatics sharehold to spawn new Houston-based subsidiary Immatics US through investing into a $60M (€54M) pot. Also partnering up with French CAR-T pioneers Cellectis, and collaborating with German Merck, MD Anderson is seemingly wanting to immerse itself in the European immuno-oncology field. As a shareholder in the German cancer immunotherapy […]

September 7, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 7 Sep 2015

A reliable technology to develop the next generation of GPCR targeted medicines

You must have heard of GPCRs, or more specifically G protein-coupled receptors. Doesn’t ring a bell? You know, it’s this large protein family of receptors that sense molecules outside the cell and trigger an inside signal. A technology called IP-One could give a large advantage to scientists working on GPCR-targeted drugs. We had the opportunity to […]

September 7, 2015 - 4 minutesmins - By Joachim Eeckhout

News and Trends 5 Sep 2015

Genzyme pays another $32.5M for cheating on one of its product’s supposed applications

Genzyme’s $22.28M (€20M) penalty wasn’t enough for the US Department of Justice to resolve its criminal marketing of Seprafilm. Sanofi’s biotech subsidiary will therefore have to pay another $32.5M (€29,2M) to avoid further legal implications. Criminal charges caught Cambridge-based Genzyme by promoting its tape-like Seprafilm for wrong allegations between 2005 and 2010, up until one year […]

September 5, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 2 Sep 2015

Alexion launches a duo of new therapies for ultra-rare diseases in the EU

Thanks to Alexion Pharmaceuticals, two ultra-rare diseases finally got the first treatment in the European Union, namely Lysosomal acid lipase deficiency (LAL-D) and Pediatric-onset hypophosphatasia. Alexion ramps up its product-pipeline. Until now, the Connecticut-based company, which comprises a market cap of about $38.5Bn (€34,2Bn), has lived mostly on sales of Soliris, the most expensive drug on […]

September 2, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 2 Sep 2015

Arderlyx’s ‘hot potato’: Sanofi changes its mind about €175M pre-clinical research deal

Paris based Sanofi has pulled out of a €176M deal with Californian clinical stage biotech Ardelyx. A licensing deal for a program of pre-clinical candidates treating renal diseases and IBS-C, similar to Tenapanor, was revoked. In February 2015, Fresno County’s Ardelyx announced its pharma-baby, Tenapanor, had passed its stage IIB clinical trials in successfully reducing serum levels of phosphate. […]

September 2, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 2 Sep 2015

Carmat’s Artificial Heart is now inside three patients – how’s it doing?

So preliminary trial results look good – it could be that the next phase will go forward too. The artificial heart of French pioneer Carmat shows several device failures but overcomes major side effects of former gadgets, such as thromboembolism or haemorrhage. Heart failure is the world’s leading cause of death. In Europe alone, 15 million patients […]

September 2, 2015 - 2 minutesmins - By Philip Hemme

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

France

High-Throughput screening of drug candidates made easier by FRETinFLOW

Biom’Up funding goes up Up UP! Surgery tech gets new pot of €31.3M VC

Biofuels from tobacco: US Tyton and French Deinove partner up

Roche adds AveXis to its SMA portfolio – determined to dominate market

Genkyotex’ NOX inhibitor candidate Fails to follow through on Phase II

Encouraging results from Tedopi Phase II trials in patients with brain metastases

A Slice of Europe: MD Anderson looks to invest in EU Immuno-Oncology

A reliable technology to develop the next generation of GPCR targeted medicines

Genzyme pays another $32.5M for cheating on one of its product’s supposed applications

Alexion launches a duo of new therapies for ultra-rare diseases in the EU

Arderlyx’s ‘hot potato’: Sanofi changes its mind about €175M pre-clinical research deal

Carmat’s Artificial Heart is now inside three patients – how’s it doing?

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!